在阿尔茨海默病中循环的短链脂肪酸:一个横截面的观察性研究
Moira Marizzoni1, Luigi Coppola2, Cristina Festari3
1Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Journal of Alzheimer's disease : JAD
|June 12, 2025
概括
肠道微生物产生短链脂肪酸 (SCFA),可能会影响阿尔茨海默病 (AD). 在阿尔茨海默氏症患者中,SCFA 形状不同,这表明潜在的诊断和治疗作用.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 生物化学 生化学
背景情况:
- 肠道微生物群的代谢物短链脂肪酸 (SCFA) 越来越多地被认为具有系统作用.
- 新出现的证据表明,肠道失调症,SCFA和神经退行性疾病 (如阿尔茨海默氏症) 之间存在潜在联系.
研究的目的:
- 在因AD (CI-AD),因AD (CI-NAD) 不引起的认知障碍和认知无障碍 (CU) 控制的个人中调查SCFA的概况.
- 探索SCFA作为AD的诊断生物标志物的潜力.
主要方法:
- 在28名CI-AD患者,29名CI-NAD患者和10名CU患者的血样本中分析SCFA水平 (乙酸盐,酸盐,丁酸盐).
- 统计分析以比较不同组的SCFA水平,并使用接收器操作特征 (ROC) 曲线评估其诊断性能.
主要成果:
- 与CU和CI-NAD组相比,CI-AD患者表现出明显更高的酸盐和酸盐水平,以及较低的丁酸盐水平 (p < 0.018).
- 乙酸在区分CI-AD和CI-NAD方面表现出高的诊断准确性 (曲线下的面积[AUC]=0.95).
- 与乙相比,神经退行生物标志物GFAP的诊断准确性较低 (AUC = 0.79).
结论:
- SCFA 档案,特别是酸盐,显示出作为区分AD相关认知障碍的潜在生物标志物的潜力.
- 对用于AD诊断和作为治疗点的SCFA进行进一步研究是有必要的.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
